LONDON - GlaxoSmithKline PLC has made an offer to take over US drug maker Human Genome Sciences Inc. that values the company at nearly $2.6 billion.
GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, said Wednesday it is offering $13 cash per share for the company. A private offer last month by GSK at the same price was rejected by HGS management.
HGS shares closed at $14.39 Tuesday on the Nasdaq exchange.
The tender offer, which is a direct approach to the target’s shareholders, will remain open for 20 days.
Human Genome Sciences, based in Rockville, Md., has a 50-50 profit sharing agreement with GSK on the lupus drug Benlysta, which won regulatory approval in the United States and Europe last year.
The two companies are also cooperating in late-stage development of darapladib, for the treatment of cardiovascular disease, and albiglutide, for type 2 diabetes.